COGT
Chart
Ratings & dials
1m · 5m · 15m · 1h · 4h · 1DAnalyst & Morningstar ratings
Consensus · Targets · MorningstarThird-party ratings, not SURVYR.'s views.
Key stats & company
What they do
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17.
Valuation and fundamentals
Valuation & fundamentals
For information only · Important disclosures
Grades vs sector
No sector grades for COGT yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.
Systematic Models
Not held by any of our 7 live models right now.
Earnings & events
COGT earningsNext report in 6 daysIn line = within 1% of the estimate.
News & catalysts
More newsInsider trades
$118.7K
$1.6M
–
Stats refreshed 2026-10-21 18:23:56 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
Get the market emails
Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdaysIndexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.
Check your inbox to confirm
We sent a link to . Tap it to start your emails. Nothing is sent until you confirm.
Not there in a minute? Check spam, or .
Dev mode No email provider here, so the confirm link is shown: Open confirm link
Free to use. No card, no ads, no auto-renew.
Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app
Coteau 0.9 · Oct 21, 2026